95% til plasmaproteiner, hovedsagelig albumin og alfa- syre- glycoprotein, med en mindre binding til lipoproteiner.
Distribution At clinically relevant concentrations of imatinib, binding to plasma proteins was approximately 95% on the basis of in vitro experiments, mostly to albumin and alpha-acid-glycoprotein, with little binding to lipoprotein.